Xeris Biopharma Holdings, Inc.
XERS
$5.48
-$0.25-4.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 101.01% | 75.22% | 46.28% | 30.01% | 11.92% |
| Total Depreciation and Amortization | 0.54% | -0.96% | -3.23% | -4.84% | -4.07% |
| Total Amortization of Deferred Charges | 12.17% | 22.92% | 32.81% | 47.00% | 36.37% |
| Total Other Non-Cash Items | 102.54% | 195.62% | 78.48% | 155.30% | 79.24% |
| Change in Net Operating Assets | -17.46% | -214.14% | -514.79% | -743.60% | -40.13% |
| Cash from Operations | 177.41% | 133.53% | 57.19% | 35.15% | 21.36% |
| Capital Expenditure | 19.82% | 25.26% | 42.29% | 67.25% | 61.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -2.65% | 30.44% | 23.02% | 253.73% |
| Cash from Investing | -114.25% | -0.84% | 35.66% | 33.81% | 181.33% |
| Total Debt Issued | -- | -100.00% | -100.00% | -100.00% | -- |
| Total Debt Repaid | -- | -- | 200.00% | -- | -- |
| Issuance of Common Stock | 1,184.77% | 1,743.88% | 518.22% | 489.90% | 198.28% |
| Repurchase of Common Stock | -191.27% | -162.70% | -152.55% | -131.79% | -270.07% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -898.40% | 100.00% | -898.40% |
| Cash from Financing | -68.51% | -65.10% | -105.44% | -106.28% | 2,342.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 866.07% | 152.34% | -85.94% | -137.57% | 107.45% |